{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:56:06Z","timestamp":1790830566646,"version":"4.1.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To establish the significance of complete pathologic response (cPR) on survival and locoregional treatment outcomes in a large US cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>cPR in hepatocellular carcinoma (HCC) is associated with improved post\u2013liver transplant (LT) outcomes. cPR rates, modality-specific differences, and predictors remain undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients were identified from the United Network for Organ Sharing (UNOS) database (2012\u20132024). cPR was defined as the absence of a viable tumor on explant pathology. Logistic regression identified predictors of cPR, Fine-Gray models estimated the incidence of cPRand Kaplan-Meier analysis assessed survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 7398 LT recipients, 2167 (29.3%) achieved cPR. Imaging\u2013pathology concordance was poor (30.5%), with imaging overestimating response in 42.6% of cases (\u03ba=0.17,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Longer waitlist time [&gt;18 vs. &lt;6\u00a0mo; odds ratio (OR): 1.94, 95% CI: 1.57\u20132.40], Y-90 (41.2%), and ablation (36.4%) were associated with higher cPR rates than transarterial chemoembolization (24.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). On multivariable analysis, yttrium-90 (Y-90) [adjusted OR (aOR): 1.89, 95% CI: 1.46\u20132.05] and ablation (aOR: 1.23, 95% CI: 1.08\u20131.39) independently increased cPR, whereas greater tumor burden and elevated alpha-fetoprotein reduced cPR. Y-90 benefit was greatest when administered \u22646 months of waitlisting (OR: 2.40, 95% CI: 1.59\u20133.61) and in all-comer candidates (OR: 1.58, 95% CI: 1.17\u20133.26). Fine-Gray analysis confirmed the highest cumulative incidence of cPR with Y-90 across transplant eligibility criteria. cPR was associated with improved 5-year overall survival (86.6% vs. 77.4%) and recurrence-free survival (76.9% vs. 63.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Nearly one-third of LT recipients with HCC achieved cPR, which was associated with improved survival. Y-90 was independently associated with higher cPR rates, particularly when administered early and among patients with higher tumor burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sla.0000000000007221","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:00:33Z","timestamp":1790827233000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Liver Transplantation for Hepatocellular Carcinoma"],"prefix":"10.1097","author":[{"given":"Benjamin","family":"Tran","sequence":"first","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Marino","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"DiNorcia","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Torabi","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadin","family":"Badran","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Florman","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirema","family":"Garcia-Reyes","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Tabrizian","sequence":"additional","affiliation":[{"name":"Recanati\/Miller Transplant Institute, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,1]]},"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:00:34Z","timestamp":1790827234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007221"}},"subtitle":["Prognostic Impact of Complete Pathologic Response and Influence of Treatment Modality\u2014A US National Database Study"],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000007221","relation":{},"ISSN":["0003-4932","1528-1140"],"issn-type":[{"value":"0003-4932","type":"print"},{"value":"1528-1140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"2026-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}